OrigAMI-2
Clinician commentary on OrigAMI-2 in the sources reviewed for this edition leads to one open question: What comparative benefit would justify replacing cetuximab, and which precursor signals do clinicians regard as sufficient only to support investigation or participation? Its leading findings: (1) enthusiasm supports further testing, not a conclusion of phase 3 superiority. (2) an active anti-EGFR benchmark coexists with regional practice variation. (3) correct molecular information must arrive before the first-line decision. 3 more findings follow. 20 of 24 screened sources are cited; not all HCPs or all public discussion.
- NCT06662786 ↗
- v1.0.0 · edition 1
- updated Oct 19, 2026
- Standard
6 findings, and what sits behind each
Select a finding to see what the full report holds for it: how many verified HCP statements and of what kind, the passages behind them, the sources and voices, and the counterview and limits it records. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
Enthusiasm supports further testing, not a conclusion of phase 3 superiority
- statements
- 14
- passages
- 12
- sources
- 7
- named voices
- 9
What the statements areViews 7Questions and uncertainty 1Clinical experience 0Comparisons 2Restated results and context 4How passages are usedSupporting a statement 22Giving context 2Recorded with the finding- Counterview: recorded
- Limitations: 3
- Feeds the Medical Affairs question
- 3 posts and articles
- 4 podcasts and video
Draws on: Design and conduct.
In the full report: the interpretation in full, all 14 statements cited to source and date, and the 7 sources linked where public.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap, since one statement can back several findings, and they show what the report kept, not how many clinicians agree.
The full OrigAMI-2 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified HCP statements, each linked to the original. Get a complete report free to see what you get.
What comparative benefit would justify replacing cetuximab, and which precursor signals do clinicians regard as sufficient only to support investigation or participation?
Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
free- 24HCP commentary sources screened
- 20sources cited by verified HCP statements
- 15found in screened sources
- 5matched to verified clinician profiles
- 14voices cited in the report
- 163verified statements, each linked to its source
- 77of them from speakers with a confirmed clinical role
- 6findings
Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context. No count estimates how many clinicians hold a view. Size (Standard) is set by the 163 verified statements. Statements from sponsors, hosts and organisations are labelled and count apart from identified clinicians.
What's inside
free| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 7 sections | Paid |
| Verified statements with short source quotes and links | 163 | Paid |
| Trial aspects mapped | 12 | Free |
| Sources with links | 20 | Counts free |
| Speaker attribution for cited voices | 14 | Paid |
Trial aspects
10 discussed · 2 no commentary · 0 incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)no commentary found | 0 | 0 |
| Secondary endpointsno commentary found | 0 | 0 |
| Population and setting | 9 | 4 |
| The comparison | 9 | 4 |
| Safety and tolerability | 4 | 3 |
| Design and conduct | 3 | 3 |
| Interpretation of precursor evidence and expectations for validation | 15 | 7 |
| Resistance rationale, molecular selection and sequencing questions | 14 | 5 |
| Pretreatment molecular work-up and exploratory refinement beyond sidedness | 20 | 5 |
| Regional practice and consequences of first-line sequencing | 5 | 4 |
| Potential ctDNA hyperselection and equitable access | 4 | 1 |
| Enrollment discussion, referral and patient information | 6 | 7 |
An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.
Sources
free| Channel | Screened | Cited | |
|---|---|---|---|
| X threads | 12 | 9 | |
| YouTube | 8 | 7 | |
| Bluesky threads | 2 | 2 | |
| Podcasts | 2 | 2 |
max 5 / quarter
- Screened window
- Jun 6, 2022 → Sep 18, 2026
- Cited window
- Sep 14, 2024 → Sep 18, 2026
- Retrieved
- Oct 19, 2026
The trial
from ClinicalTrials.gov- Title
- A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Registry
- NCT06662786
- Study IDs
- 61186372COR3001 · 2024-513852-13-00 (EUCT number)
- Sponsor
- Janssen Research & Development, LLC
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 1,000 estimated
- Start
- 2024-10-18 actual
- Primary completion
- 2028-12-15 estimated
- Primary endpoint
- Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)
- Interventions
- 6 registered
Scope and limits
freeThis report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
- 72 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Multiple audio and video versions repeat the same PeerView discussion.
- Some passages on molecular selection, ctDNA, access and treatment choices were not fully assessed. A complete account of rare-mutation immunotherapy selection is also unavailable.
- No protocol text or publication reporting results for NCT06662786 was available. The report therefore cannot independently appraise detailed methods or establish comparative efficacy or safety.
- Regulatory information was incomplete. Speakers' references to lung-cancer use are development context, not an assessment of a colorectal-cancer indication.
- Publication and posting dates do not necessarily identify the date of the underlying session or the first availability of its data.
- Some speakers remain unidentified, and some named social-media authors lack confirmed clinical roles. Their statements cannot be used to infer additional verified HCP agreement.
- Historical enrollment announcements do not establish current recruitment, access at a particular site or individual patient eligibility.
How reports are built and checked: Methods.
Editions and corrections
freeLast checked for new commentary Oct 19, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.
Cite this report
Erudio Health. OrigAMI-2 (NCT06662786): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 19, 2026. https://www.erudio.com/reports/origami-2-nct06662786
For your AI agent
The same record as JSON or Markdown, or through the Erudio MCP server
curl https://www.erudio.com/reports/origami-2-nct06662786.json
curl https://www.erudio.com/reports/origami-2-nct06662786.md
# MCP (https://mcp.erudio.com/mcp)
get_report_card({ "slug": "origami-2-06662786" })release 3556367d9ca67a062558a627acee83cbb74a9d3d42ccae5ba09b47f184c17e4d